<DOC>
	<DOCNO>NCT02448901</DOCNO>
	<brief_summary>The influence different dos edoxaban physical characteristic clot thrombin generation kinetics blood sample study vitro spike blood sample collect patient treated heart failure ( without hypercoagulability ) healthy volunteer ( without hypercoagulability ) . This vitro experiment help u : ( ) detect qualitative anticlotting property edoxaban . ( ii ) quantify anticlotting property edoxaban .</brief_summary>
	<brief_title>Influence Edoxaban Coagulability Thrombin Generation : An Vitro Study Focusing Thrombelastography</brief_title>
	<detailed_description>Experimental protocol 1 . On day experiment blood sample collect 3.2 % citrate tube . 2 . One citrate blood tube centrifuge collect plasma biomarker measurement ( C-reactive protein ( CRP ) , fibrinogen , von Willebrand factor ( vWF ) , interleukin ( IL ) -6 , p-selectin , plasminogen activator inhibitor ( PAI ) -1 , matrix metalloproteinase ( MMP ) -9 ) . 3 . Blood sample incubate different concentration edoxaban ( edoxaban , subtherapeutic range - 30 nM , therapeutic range -300 nM , supratherapeutic range- 900 nM ) ( 3 ) . A ) Cora® Hemostasis Analyzer System ( Cora® ) use assess qualitative quantitative assessment hemostatic property blood sample presence absence edoxaban . The CORA integrate computer module Ethernet connection capability provide continuous resonance-frequency viscoelasticity measurement use disposable four-channel microfluidic cartridge determine simultaneous maximal platelet-fibrin clot strength , fibrin clot strength , response antiplatelet agent anticoagulant . The cartridge four channel - citrate Kaolin ( CK ) channel measure platelet-fibrin clot strength , anti-Xa channel , DTI channel FFC channel measure contribution functional fibrinogen . In addition , use V-curve software , follow parameter thrombin generation kinetics evaluate CK channel- R - Period time latency time blood place TEG® analyzer initial fibrin formation . This represent enzymatic portion coagulation . K - K time measure speed reach certain level clot strength . This represent clot kinetics . alpha - measure rapidity fibrin build-up cross-linking ( clot strengthen ) . This represent fibrinogen level . MA - Maximum Amplitude direct function maximum dynamic property fibrin platelet bonding via GPIIb/IIIa represent ultimate strength fibrin clot . This represent platelet function/aggregation . TMRTG - Time maximum rate thrombus generation . MRTG - Maximum rate thrombus generation . TG - Total thrombus generate . TMRL - Time maximum rate lysis MRL - Maximum rate lysis L - Total lysis D - Delta difference R time time initial split point ( SP , mins ) TEG tracing ( R - SP ) , represent time interval great clot growth secondary peak thrombin generation . B ) Calibrated Automated Thrombogram® ( CAT ) System : Lag time , peak thrombin production , mean velocity rate index endogenous thrombin potential ( ETP ) assess calibrate automated thrombogram platelet poor plasma ( Thrombinoscope Stago ) .</detailed_description>
	<mesh_term>Heart Failure</mesh_term>
	<mesh_term>Thrombin</mesh_term>
	<mesh_term>Edoxaban</mesh_term>
	<criteria>Patients heart failure ( class IIV ) eligible enrollment : 1 . Patient must document symptomatic chronic HF least 3 month prior screen . Exacerbation chronic HF define symptom worsen dyspnea fatigue , objective sign congestion peripheral edema ascites , and/or adjustment prehospitalization HF medication . 2 . Subject must document LVEF less equal 40 % within 3 month study . If one LVEF available , recent one use , must less equal 40 % . The ejection fraction determine one follow method : echocardiogram , nuclear multigated acquisition ( MUGA ) scan , cardiac MRI , cardiac CT scan , leave ventriculography . 3 . Patient must receive appropriate HF treatment appropriate dosing per guideline : Diuretic ( require study entry ) Reninangiotensin system ( RAS ) inhibitor ACE inhibitor , ARB intolerant ACE inhibitor , vasodilator therapy hydralazine nitrate intolerant ACE inhibitor ARB Beta blocker therapy Aldosterone antagonist therapy . 4 . Patient must complete prophylactic anticoagulation ( enoxaparin , warfarin , heparin , etc ) least one week study . 5 . Each patient ( legally acceptable representative ) must sign informed consent form ( ICF ) indicate understands purpose willing participate study . For Healthy Subjects : subject currently antiplatelet therapy agent know influence platelet function coagulation . For Subjects Heart Failure : 1 . Hemodynamic instability , active bleeding bleeding diatheses , oral anticoagulation therapy , leukocyte count &lt; 3,000/mm3 , platelet count &lt; 100,000/mm3 , aspartate aminotransferase alanine aminotransferase level ≥ 3 time upper normal , creatinine &gt; 2mg/dL . 2 . Patient severe concomitant disease : Atrial fibrillation ( AFib ) another condition require chronic anticoagulation .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2015</verification_date>
</DOC>